nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

24.07.2019 | Original Article

Quality of life in patients with midgut NET following peptide receptor radionuclide therapy

verfasst von: Milka Marinova, Martin Mücke, Felix Fischer, Markus Essler, Henning Cuhls, Lukas Radbruch, Shiwa Ghaei, Rupert Conrad, Hojjat Ahmadzadehfar

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Objectives

There is convincing evidence that peptide receptor radionuclide therapy (PRRT) using ¹⁷⁷Lu-DOTATATE compared to octreotide therapy has a positive effect on overall survival and progression-free survival in midgut neuroendocrine tumors (NET). The current study analyzed health-related quality of life (QoL) in patients undergoing PRRT with a special focus on differences in functional performance.

Materials and methods

In our study, 70 patients (39 men or 31 female) suffering from midgut NET were included, with a mean age of 64.2 years. Functional performance was assessed by the index of the Eastern Cooperative of Oncology Group (ECOG). Thirty-three patients (47%) showed ECOG 0, 31 patients (44%) ECOG 1, and six patients (9%) ECOG 2. Health-related QoL was assessed by the EORTC QLQ-C30 questionnaire filled in at baseline and 3 months after each PRRT cycle.

Results

The median cumulative administered activity was 27.4 GBq. Global health status significantly improved compared to baseline status after 1st (p = 0.05), 2nd (p = 0.004), and 3rd (p = 0.04) treatment cycle. Analyzing specific aspects of QoL, emotional functioning significantly improved after 1st and 2nd treatment cycle (both p < 0.001) as well as after 3rd cycle (p = 0.001). With regard to cognitive functioning, there was a significant improvement after 1st and 2nd treatment cycle (p = 0.003 and p = 0.05 respectively). With regard to alleviation of somatic symptoms, a significant reduction in pain and diarrhea was observed after the 2nd cycle (p = 0.038) and 3rd cycle (p = 0.036). Furthermore, changes in QoL in relation to functional performance status as assessed by ECOG were analyzed. There were no significant differences with regard to QoL alterations between patients with high (ECOG 0 or 1) and moderate performance status.

Conclusion

Our study confirmed an equally positive effect of PRRT on quality of life in midgut NET patients with high or moderate functional status in terms of increasing global health, functional status, and alleviating symptoms.

Nur mit Berechtigung zugänglich

Yordanova A, Ahmadzadehfar H, Gonzalez-Carmona M, Strassburg C, Mayer K, Feldmann G, et al. A step-by-step clinical approach for the management of neuroendocrine tumours. Horm Metab Res. 2017;49:77–85. https://doi.org/10.1055/s-0042-121894.CrossRefPubMed

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72. https://doi.org/10.1200/JCO.2007.15.4377.CrossRefPubMed

Bottomley A. The cancer patient and quality of life. Oncologist. 2002;7:120–5. https://doi.org/10.1634/theoncologist.7-2-120.CrossRefPubMed

Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:1556–7. https://doi.org/10.1056/NEJMc1409757.CrossRefPubMed

Fisher GA Jr, Wolin EM, Liyanage N, Pitman Lowenthal S, Mirakhur B, Pommier RF, et al. Patient-reported symptom control of diarrhea and flushing in patients with neuroendocrine tumors treated with lanreotide depot/autogel: results from a randomized, placebo-controlled, double-blind and 32-week open-label study. Oncologist. 2018;23:16–24. https://doi.org/10.1634/theoncologist.2017-0284.CrossRefPubMed

Meyer T, Qian W, Caplin ME, Armstrong G, Lao-Sirieix SH, Hardy R, et al. Capecitabine and streptozocin +/− cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. Eur J Cancer. 2014;50:902–11. https://doi.org/10.1016/j.ejca.2013.12.011.CrossRefPubMed

Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, et al. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1411–22. https://doi.org/10.1016/S1470-2045(17)30471-0.CrossRefPubMed

Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13. https://doi.org/10.1056/NEJMoa1003825.CrossRefPubMed

Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27:4656–63. https://doi.org/10.1200/JCO.2009.22.8510.CrossRefPubMed

10.

Vinik A, Bottomley A, Korytowsky B, Bang YJ, Raoul JL, Valle JW, et al. Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: results from an international phase III trial. Target Oncol. 2016;11:815–24. https://doi.org/10.1007/s11523-016-0462-5.CrossRefPubMed

11.

Bodei L, Kwekkeboom DJ, Kidd M, Modlin IM, Krenning EP. Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer. Semin Nucl Med. 2016;46:225–38. https://doi.org/10.1053/j.semnuclmed.2015.12.003.CrossRefPubMed

12.

Ilan E, Sandstrom M, Wassberg C, Sundin A, Garske-Roman U, Eriksson B, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med. 2015;56:177–82. https://doi.org/10.2967/jnumed.114.148437.CrossRefPubMed

13.

Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–62. https://doi.org/10.1200/JCO.2005.08.066.CrossRefPubMed

14.

Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35. https://doi.org/10.1007/s00259-011-1902-1.CrossRefPubMed

15.

Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:925–33. https://doi.org/10.1007/s00259-013-2677-3.CrossRefPubMed

16.

Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grunwald F, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014;55:183–90. https://doi.org/10.2967/jnumed.113.125336.CrossRefPubMed

17.

van Vliet EI, van Eijck CH, de Krijger RR, Nieveen van Dijkum EJ, Teunissen JJ, Kam BL, et al. Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2015;56:1647–53. https://doi.org/10.2967/jnumed.115.158899.CrossRefPubMed

18.

Sabet A, Haslerud T, Pape UF, Ahmadzadehfar H, Grunwald F, Guhlke S, et al. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:205–10. https://doi.org/10.1007/s00259-013-2547-z.CrossRefPubMed

19.

Ezziddin S, Sabet A, Heinemann F, Yong-Hing CJ, Ahmadzadehfar H, Guhlke S, et al. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. J Nucl Med. 2011;52:1197–203. https://doi.org/10.2967/jnumed.111.090373.CrossRefPubMed

20.

Horsch D, Prasad V, Baum RP. Longterm outcome of peptide receptor radionuclide therapy (PRRT) in 454 patients with progressive neuroendocrine tumors using yttrium-90 and lutetium-177 labelled somatostatin receptor targeting peptides. J Clin Oncol. 2008;26:4517.CrossRef

21.

Yordanova A, Wicharz MM, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, et al. The role of adding somatostatin analogues to peptide receptor radionuclide therapy as a combination and maintenance therapy. Clin Cancer Res. 2018;24:4672–9. https://doi.org/10.1158/1078-0432.CCR-18-0947.CrossRefPubMed

22.

Sabet A, Khalaf F, Yong-Hing CJ, Haslerud T, Ahmadzadehfar H, Guhlke S, et al. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement. Nuklearmedizin. 2014;53:54–9. https://doi.org/10.3413/Nukmed-0614-13-08.CrossRefPubMed

23.

Sabet A, Ezziddin K, Pape UF, Reichman K, Haslerud T, Ahmadzadehfar H, et al. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. Eur J Nucl Med Mol Imaging. 2014;41:505–10. https://doi.org/10.1007/s00259-013-2601-x.CrossRefPubMed

24.

Sabet A, Ezziddin K, Pape UF, Ahmadzadehfar H, Mayer K, Poppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2013;54:1857–61. https://doi.org/10.2967/jnumed.112.119347.CrossRefPubMed

25.

Bergsma H, Konijnenberg MW, van der Zwan WA, Kam BL, Teunissen JJ, Kooij PP, et al. Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging. 2016;43:1802–11. https://doi.org/10.1007/s00259-016-3382-9.CrossRefPubMedPubMedCentral

26.

Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19. https://doi.org/10.1007/s00259-014-2893-5.CrossRefPubMed

27.

Procopio G, Ratta R, de Braud F. Improved quality of life is the way to longer life. Lancet Oncol. 2016;17:862–3. https://doi.org/10.1016/S1470-2045(16)30158-9. www.thelancet.com/oncology.CrossRefPubMed

28.

Velanovich V. The association of quality-of-life measures with malignancy and survival in patients with pancreatic pathology. Pancreas. 2011;40:1063–9. https://doi.org/10.1097/MPA.0b013e31821ad8eb.CrossRefPubMed

29.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427.CrossRefPubMedPubMedCentral

30.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed

31.

Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.

32.

Cameron AC, Pravin KT. Microeconometrics using Stata revised edition. College Station TX:Stata Press; 2010.

33.

Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modeling using Stata. 3rd ed. College Station TX:Stata Press; 2012. p. 1–2.

34.

Martini C, Gamper EM, Wintner L, Nilica B, Sperner-Unterweger B, Holzner B, et al. Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours. Health Qual Life Outcomes. 2016;14:127. https://doi.org/10.1186/s12955-016-0527-2.CrossRefPubMedPubMedCentral

35.

Soga J, Yakuwa Y, Osaka M. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res. 1999;18:133–41.PubMed

36.

Sarshekeh AM, Halperin DM, Dasari A. Update on management of midgut neuroendocrine tumors. Int J Endocr Oncol. 2016;3:175–89. https://doi.org/10.2217/ije-2015-0004.CrossRef

37.

Severi S, Grassi I, Nicolini S, Sansovini M, Bongiovanni A, Paganelli G. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. Onco Targets Ther. 2017;10:551–7. https://doi.org/10.2147/OTT.S97584.CrossRefPubMedPubMedCentral

38.

Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-Dotatate in the phase III NETTER-1 trial. J Clin Oncol. 2018;36:2578–84. https://doi.org/10.1200/JCO.2018.78.5865.CrossRefPubMedPubMedCentral

39.

Zhang J, Kulkarni HR, Singh A, Baum RP. Delayed response (partial remission) 3 years after peptide receptor radionuclide therapy in a patient participating in the NETTER-1 trial. Clin Nucl Med. 2019;44:223–6. https://doi.org/10.1097/RLU.0000000000002456.CrossRefPubMed

40.

Land SR, Walcott FL, Liu Q, Wickerham DL, Costantino JP, Ganz PA. Symptoms and QOL as predictors of chemoprevention adherence in NRG oncology/NSABP trial P-1. J Natl Cancer Inst. 2016;108(4):pii: djv365 https://doi.org/10.1093/jnci/djv365.

41.

Verbrugghe M, Verhaeghe S, Lauwaert K, Beeckman D, Van Hecke A. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev. 2013;39:610–21. https://doi.org/10.1016/j.ctrv.2012.12.014.CrossRefPubMed

42.

Fassino S, Amianto F, Sobrero C, Abbate DG. Does it exist a personality core of mental illness? A systematic review on core psychobiological personality traits in mental disorders. Panminerva Med. 2013;55:397–413.PubMed

43.

Martini C, Buxbaum S, Rodrigues M, Nilica B, Scarpa L, Holzner B, et al. Quality of life in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy: information from a monitoring program in clinical routine. J Nucl Med. 2018;59:1566–73. https://doi.org/10.2967/jnumed.117.204834.CrossRefPubMed

44.

Marinova M, Mucke M, Mahlberg L, Essler M, Cuhls H, Radbruch L, et al. Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30. Eur J Nucl Med Mol Imaging. 2018;45:38–46. https://doi.org/10.1007/s00259-017-3816-z.CrossRefPubMed

45.

Zandee WT, Brabander T, Blazevic A, Kam BLR, Teunissen JJM, Feelders RA, et al. Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2019;104:1336–44. https://doi.org/10.1210/jc.2018-01991.CrossRefPubMed

46.

Dong C, Liu Z, Wang F. Peptide-based radiopharmaceuticals for targeted tumor therapy. Curr Med Chem. 2014;21:139–52.CrossRefPubMed

47.

Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, et al. Personalized (177)Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46:728–42. https://doi.org/10.1007/s00259-018-4209-7.CrossRefPubMed

Titel: Quality of life in patients with midgut NET following peptide receptor radionuclide therapy
verfasst von: Milka Marinova
Martin Mücke
Felix Fischer
Markus Essler
Henning Cuhls
Lukas Radbruch
Shiwa Ghaei
Rupert Conrad
Hojjat Ahmadzadehfar
Publikationsdatum: 24.07.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04431-3

Springer Medizin

Abstract

Objectives

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2019

Al18F-NOTA-octreotide and 18F-SiFAlin-TATE: two ‘new kids on the block’ in somatostatin receptor imaging

Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003

Molecular imaging of impulse control disorders in Parkinson’s disease

EANM commitment towards involvement and engagement of patients and the public: learning from the UK experience

A multiparametric analysis based on DCE-MRI to improve the accuracy of parotid tumor discrimination

Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors